May 2023 in “Research Square (Research Square)” Patients with acne and insulin resistance have different blood metabolites compared to those with only acne, which could help in diagnosis and treatment.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
March 2023 in “Journal of Applied Biomedicine” Oleanolic acid improved hair growth in mice by affecting hair growth pathways and reducing inflammation.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
April 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Retinoic acid helps activate hair growth in people with common hair loss by working on a specific cell growth pathway.
5 citations
,
October 2024 in “International Journal of Molecular Sciences” Piperonylic acid may help hair growth and treat hair loss.
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
75 citations
,
January 2014 in “Archiv Der Pharmazie” Jasmonic acid and its derivatives play important roles in plant health and have potential uses in medicine and agriculture.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
July 1988 in “Journal of The American Academy of Dermatology” Various dermatologic treatments were effective for skin conditions like acne, rosacea, hair loss, and psoriasis from December 1986 to December 1987.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
7 citations
,
May 2022 in “Indonesian Journal of Science and Technology” Compounds from Etlingera alba may help treat Triple Negative Breast Cancer.
2 citations
,
April 2024 in “Science & Technology Indonesia” Albizia saponaria bark extract, especially the ethyl acetate fraction, is a strong antioxidant source.
1 citations
,
May 2022 in “Research Square (Research Square)” Acetate helps reduce depression in rats with PCOS by lowering specific gene expression and DNA changes in the brain.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
1 citations
,
June 2019 in “Journal of Cutaneous Immunology and Allergy” Squaric acid dibutylester can cause severe skin reactions in people with allergies.
12 citations
,
July 2017 in “International Journal of Cosmetic Science” N‐AOHPA is a promising alternative to traditional surfactants for better hair conditioning.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
4 citations
,
December 2022 in “Evidence-based Complementary and Alternative Medicine” Phenolic compounds from Quercus acutissima leaves, especially casuarinin, may help treat acne.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
June 2026 in “Journal of Investigative Dermatology” Retinoic acids temporarily change skin stem cells to a slower cycle and more differentiated state.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.